Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: February 22, 2023
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
Journal: Clinical and experimental rheumatology
Published: August 12, 2020
Showing 1-2 of 2
Last Updated: 09/26/2026